Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Terminated Phase 3 Interventional Results available

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

NCT00004010
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
37
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Hydrolyzed Collagen and Vitamin C on Explosive Performance

NCT04437758
View directory record Official record
Conditions
Collagen Synthesis, Rate of Force (RFD) Development
Interventions
Collagen and Vitamin C powder mix nutritional intervention, Maltodextrin placebo powder, Maximum power training exercise
Dietary Supplement · Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 30 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Comparing Use of a Digital Health System of Pelvic Floor Exercise Program to Kegel Exercises in Stress Urinary Incontinence

NCT03632447
View directory record Official record
Conditions
Stress Urinary Incontinence, Mixed Urinary Incontinence
Interventions
Leva, PFDx
Device
Lead sponsor
Renovia, Inc.
Industry
Eligibility
18 Years to 89 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Beverly Hills, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

NCT00003294
View directory record Official record
Conditions
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 31, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

NCT04176419
View directory record Official record
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 31, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Selinexor
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Irvine, California • Laguna Hills, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Utility of Long-acting Local Anesthetic Agents in Reducing Post-operative Opioid Requirements Following Rhinoplasty

NCT04377204
View directory record Official record
Conditions
Pain, Postoperative, Local Anesthetic
Interventions
marcaine bupivacaine, Lidocaine
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00244985
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 31, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional

DMT310-005 Topical in the Treatment of Acne Rosacea

NCT05108025
View directory record Official record
Conditions
Acne Rosacea
Interventions
Topical Powder, Placebo Topical Powder
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 31, 2026, 5:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Group Intervention on Vaccine Confidence

NCT05891626
View directory record Official record
Conditions
Vaccination Refusal
Interventions
Group intervention
Behavioral
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Puyallup, Washington
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

NCT00352521
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy

NCT05370612
View directory record Official record
Conditions
Type2Diabetes, Pregnancy in Diabetic
Interventions
Dexcom G6 CGM, Participant Finger Stick Glucose Monitoring
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

NCT00060905
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Depakote ER)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
18
States / cities
Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Early Phase 1 Interventional

Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

NCT03682094
View directory record Official record
Conditions
Dysphagia
Interventions
VSL#3
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

NCT00930202
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Conivaptan (Vaprisol)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 31, 2026, 5:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise and Carotid Artery Function in Metabolic Syndrome

NCT07430839
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
exercise, Diagnostics, Inhaled CO2-mixed air
Behavioral · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 31, 2026, 5:58 AM EDT
Completed No phase listed Observational

Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00098566
View directory record Official record
Conditions
Lymphoma, Quality of Life
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 31, 2026, 5:58 AM EDT
Completed No phase listed Observational

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

NCT00281801
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, Quality of Life Assessments
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

NCT00945945
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine (DLX), Placebo (PLA)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Montgomery, Alabama • Phoenix, Arizona • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Online Parental Education Project to Increase Fruit and Vegetable Intake and Active Playtime Among Toddlers

NCT05085041
View directory record Official record
Conditions
Eating Behavior
Interventions
Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 31, 2026, 5:58 AM EDT